Pharmaceuticals

FDA Grants 510(k) Approval to Cresilon’s TraumaGel for Temporary External Control of Moderate to Severe Bleeding

bexib
By bexib 0 Min Read

Cresilon works to stop life-threatening bleeding within seconds, providing a valuable tool to military, emergency medical services and healthcare workers.

You Might Also Like

FDA approves two Abbott blood glucose monitoring systems

Efcitra demonstrates non-inferiority to insulin glargine and degludec in type 2 diabetes

Arizona oncology chief says AI could help solve cancer’s ‘ZIP code lottery’ as health disparities persist

University of Liverpool launches new biotech spin-out company Galytx

FDA Grants Fast Track Designation to Clarity Pharmaceuticals’ Novel Treatment for PSMA-Positive Prostate Cancer Lesions

Share This Article
Previous Article The virtues of failing fast
Next Article Citi Sees NZD Weakened Due to US Election Uncertainty Investing.com – Investorempires.com
Leave a Comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Stay Connected

Latest News

China’s seapower expands as US shipyards decline
Manufacturing
Print advertising is an e-commerce opportunity
Retail & E-commerce
Top 6 banking trends to grow across Asia in 2025
Fintech
The Difference Between Direct Carrier Appointments and Producer Sub-Codes
Insurance